News
The day at a glance · 4 min read
Mood · Selective
+15
Sentiment, −100 to +100
DLBCL Progression Risk Reduction
51%
Regeneron Sanofi Upfront
$1.00B
Potential Milestones
$7.00B
Key driverStrong oncology trial readouts from AbbVie and Genmab offset by vaccine sector volatility and valuation concerns across major pharma names
Daily briefHealthcare· Money365.Market AI ·

AbbVie Cancer Data Surges; Vaccine Stocks Retreat

Epcoritamab cut DLBCL progression risk by 51% in Phase 3; Moderna and Novavax reverse gains amid sector volatility

Big Pharma & Biotech

Bullish

AbbVie Payout Ratio

190.40%
ABBVREGNPFE
AbbVie (ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 data showing epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus standard R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma, improving progression-free survival. The trial represents the first Phase 3 study to demonstrate meaningful benefit from a bispecific antibody in the frontline DLBCL setting.
AbbVie (ABBV) closed at $263, up 14.18% over twelve months, though the company maintains a payout ratio of 190.40%, distributing nearly twice what it reports as profit.
Regeneron Pharmaceuticals (REGN) expanded its long-running antibody alliance with Sanofi in early October 2026, receiving $1.00 billion upfront with potential future milestone payments worth up to $7.00 billion. The company reported new clinical data across oncology and obesity programs, including ubamatamab in low-grade serous ovarian cancer and next-generation long-acting immunology treatments. The alliance expansion and pipeline updates highlight Regeneron (REGN)'s strategy to broaden its portfolio beyond current blockbusters.
Pfizer (PFE) traded at around $27, up 5.18% over twelve months while yielding 6.19%, though the company paid out 226.32% of its earnings to maintain its dividend. The healthcare sector posted a 36.4% gain over the past six months, beating the S&P 500, though individual company valuations remain under scrutiny. Astellas announced 21 abstracts from its oncology portfolio will be presented at ESMO 2026, taking place October 23-27 in Madrid, spanning prostate, urothelial, gastric, lung and pancreatic cancers.

Vaccine Sector Volatility

Bearish

Moderna Session Decline

6%

Moderna Prior Session Gain

7%

Moderna 30-Day Return

28.8%

Novavax Session Decline

11%

Novavax Prior Session Gain

20%
MRNANVAX
Moderna (MRNA) shares declined 6% after gaining 7% in the previous session following reports of a suspected pneumonic plague case in Russia. The company appointed former executive Juan Andres as its new Chief Operating Officer in a newly created role, with the stock down 7.8% over the past week yet posting a 28.8% thirty-day share price return despite the recent reversal. Analysts questioned whether the stock could be 57% above fair value following recent volatility and the new executive appointment.
Novavax (NVAX) shares fell 11% after gaining 20% on Tuesday, retreating from the prior session's surge that followed the Russian plague case reports. Citi assessed vaccine sector volatility as both companies experienced sharp reversals from their Tuesday gains, reflecting the speculative nature of the recent moves tied to the infectious disease headline.

Dermatology & Immunology

Neutral
JNJBMY
Johnson & Johnson (JNJ) reported new two-year Phase 3 ICONIC-TOTAL data showing its oral peptide ICOTYDE (icotrokinra) maintained skin clearance and consistent safety in adults and adolescents with high-impact plaque psoriasis through Week 112. The results highlight ICOTYDE's potential appeal as a once-daily, targeted oral alternative for difficult-to-treat psoriasis areas including scalp, genital skin, hands, feet and nails. The long-term data positions the therapy as a differentiated option in the crowded psoriasis market.
Bristol Myers Squibb (BMY) continued its launch of Sotyktu (deucravacitinib) for psoriatic arthritis five months into U.S. commercialization, with rheumatologists increasingly adding the oral TYK2 inhibitor to their treatment armamentarium according to Spherix Global Insights research. Limited experience, access friction, and questions around joint efficacy have tempered early launch momentum despite growing prescriber adoption and enthusiasm for TYK2 differentiation. The therapy's role in the PsA treatment algorithm continues to take shape as clinicians gain experience with the novel mechanism.

MedTech & Operations

Neutral
ISRGGILD
Intuitive Surgical (ISRG) was discussed by Jim Cramer on Mad Money on October 6 regarding whether the robotic surgery company represented a broken stock rather than a broken company. The shares traded at around $404, down 7.82% over twelve months, with the media commentator citing concerns related to Johnson & Johnson (JNJ) as the primary objection rather than issues with the company itself.
Gilead Sciences (GILD) signed a five-year DevOps agreement with Cognizant that will combine life sciences knowledge with technical services to aid the company's processes. The arrangement reflects ongoing pharmaceutical industry focus on operational efficiency and technology integration to support drug development and commercial activities.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy